LEE ANN L. 4

4 · Prime Medicine, Inc. · Filed Aug 5, 2025

Form 4

Period: 2025-08-01

Chief Technical Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2025-08-01−180,995→ 0 total
Exercise: $12.30Exp: 2033-03-31→ Common Stock (180,995 underlying)
Award
Stock Option (right to buy)
2025-08-01+180,995→ 180,995 total
Exercise: $4.04Exp: 2033-03-31→ Common Stock (180,995 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-08-01−180,995→ 0 total
Exercise: $8.49Exp: 2034-02-21→ Common Stock (180,995 underlying)
Award
Stock Option (right to buy)
2025-08-01+180,995→ 180,995 total
Exercise: $4.04Exp: 2034-02-21→ Common Stock (180,995 underlying)

Footnotes (2)

[F1]Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
[F2]This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Documents

1 file